Value2Wealth Investor

By God’s grace, the day has finally arrived when TechNVision has turned into a 100-bagger for my Value2Wealth blog followers friends as well. I first wrote about TechNVision in October 2005 when it was priced at just ₹45. Today, it has reached ₹4597—a remarkable increase of about 102 times in less than 9 years, with a CAGR of 68%. Old Post Link : value2wealth.blogspot.com/2015/10/technv… To be honest, I feel fortunate, as replicating this success would be slim. I made 100-bagger but in that process I lost lot of quality followers friends on twitter because I use to bombard with every NEWS or other details on TechNVision very frequently . I was very confident in the business's prospects. While it once seemed untouchable, it is now part of MEGATrends like Data for Generative AI/ Enterprise AI, data purging and archiving for data centers, and data compliance I had mentioned this stock as bamboo value stock pick in 2015 , I was expecting to become bamboo in 3-4 years but it took almost 9 years. Holding for 9 year was very difficult part because lot of time I flustered with result , some time with ASM , GSM .

@Value2WealthIND Solix mentioned in Comparison with Informatica, IBM infosphere, Opentext, Microsoft Purview in the data lifecycle management space in the AI Journal. Worth a read 📖 aijourn.com/data-lifecycle…

@Value2WealthIND NSE listing just the start in Solix's space i feel. Why?👇 1. SAP aquired Reltio (Making master data AI ready) 2. Open AI aquired Torch (Patient health record management) 3. Anthropic aquired coefficient Bio (Uses AI to boost efficiency in drug discovery and biological research)

@market_timer Yes , they never cared about stock price thats why I surprised.

@Value2WealthIND I have seen Sika interplant also getting listed in NSE recently without any notice.Intention is to increase the liquidity, get noticed but why at this point remains a question esp knowing how frugal they are with spendings and also how they have never cared on its market pricing.

TechNVision listing to NSE is still mystery to me . NSE listing get initiated by company and The company submits a formal application to the NSE under the "New Listing" and there is compliance overhead. TechNVision don't share even simple investor presentation why they would do all these efforts. I suspect it is requested by some big name . Block deal on the card . What is your view ? @Arunstockguru @market_timer @growth_picker or anyone want to chip in

Shashank, I’m a regular viewer of your YouTube channel. I’m pretty sure you may not have even heard of TechNVision yet. It’s listed on both BSE and NSE and, in my view, is one of the strongest AI proxy plays in the Indian microcap space. What really stands out is the leadership team — honestly among the best I’ve seen in Indian microcap tech companies. Don’t take my word for it though. Have a look at what AI itself says about the company here: gemini.google.com/share/1ab0f548… Please read it fully and then decide for yourself. Guys, what do you think? If you agree, reply with: “Consider TechNVision as AI Play in Webinar".

Hosting a AI Supercycle Webinar! - Limited Seats 🗓️ 24th May | 7 PM - Indian AI value chain Exporters (3 companies) - US picks & shovels players enabling AI (5 USA) - Complete breakdown of the AI value chain and biggest opportunities Link: superprofile.bio/e/_ORHVMKj

I asked AI about Solix AI drug discovery platform and it is praising too much , it says Solix is trying to made operating system for medicine . Link : gemini.google.com/share/12b31d96…

@Value2WealthIND Adding to the above, again why Quantum + AI is a game changer in pharma is highlighted in the below post. Solix pivot looks a solid path forward. linkedin.com/pulse/why-90-d…

Following is recent linkedin post from Sai GundaVelli of Solix Technologies ( TechNVision) on stepping into #Pharma AI Drug Discovery . < Stepping into Pharma Journey and Why ? As many of you know, Solix Technologies, Inc. has long been recognized for Enterprise Data Management—helping organizations optimize storage, compute, and governance at scale. So yes, stepping into #Pharma with Solix EAI Pharma seemed like a big leap. It was. But it’s also was an opportunity we couldn’t ignore. #Drugdiscovery is one of the most complex, expensive, and time-consuming challenges in the world. The convergence of #data, #AI, and #quantumscience is creating a moment where meaningful acceleration is finally possible—and we believe we can play a significant role. Here’s how we’re bringing it all together: Solix EAI Pharma at the core, combines quantum-level simulation, AI-driven prediction, and intelligent automation into a unified drug discovery engine. Goes beyond pattern recognition → models real molecular behavior. Integrates semantic content libraries and molecular/protein datasets. Built with enterprise-grade security, governance, and #datasovereignty. Enables scalable, trustworthy discovery at speed Why Quantum + AI matters - Traditional AI learns from historical patterns. Quantum-based approaches simulate the physics of molecules—electrons, bonds, and reactions. The result - Better decisions earlier → fewer late-stage failures → lower cost and faster timelines Solix CDP (Cloud Data Platform) - An infinitely scalable platform to unify: - Historical data (including failed experiments) - Active research pipelines - Legacy discoveries In Pharma, failed pursuits are often ignored. We see them as critical learning signals to train better AI models and enable a “fail fast, learn faster” approach. Solix EDG (Enterprise Data Governance) - End-to-end governance for data and AI—ensuring trust, compliance, and responsible innovation. Solix ECS (Enterprise Content Services)Supports clinical and regulatory ecosystems: - eTMF (trial master files) - EDC (clinical data capture) Trial operations and complianceAll while addressing global data sovereignty challenges. Beyond technology — a broader mission of our goal is not just to accelerate drug discovery, but to help reduce the cost of medicine and improve access globally. Through our CSR digital initiatives at Touch-A-Life Foundation. #TALHospitals - Global Virtual Hospital #TALMedora - Social platform connecting Doctors, Hospitals, Patients, Pharmaceuticals and Wellness care. We are also exploring pathways to connect innovation with real-world #impact—including enabling early access ecosystems for clinical research and trials. When you combine data, AI, quantum science, governance, and purpose-driven platforms, the opportunity is significant. We’re just getting started. If you’re exploring the future of Pharma, AI, or drug discovery—let’s connect. <> Source : linkedin.com/posts/saigunda…

TechNVision ( Solix Technologies) and founder CEO Sai Gundavelli got Data Transformation Excellence Award 2026 by "The Silicon Review" Congratulations to team Solix . thesiliconreview.com/magazine/profi… thesiliconreview.com/magazine/profi…

Garden reach shipbuider ( GRSE ) declared excellent result , given just after ipo as value pick around just 110 now around 3000, no one was discussing about that time. value2wealth.blogspot.com/2019/07/garden… Regret, stock market full of regrets, currently holding only 30% of original quantity.

@Value2WealthIND Another Partnership: Quadient has announced the global expansion of its Inspire Digital Vault solution in partnership with Solix Technologies to North and South America globenewswire.com/news-release/2…

If you want to master the art of the 'cash call' and sector rotation, timing market by identifying phases of market cycle , this interview of @Gautam__Baid with @NeerajCNBC is a must-watch. It’s essentially a bible , but need to create your own strategy around this. I managed to nail the 2018 cycle with 40% cash, but I was caught a bit off guard this time with only 12%. This video is a great resource for anyone looking to refine their strategy and avoid the pitfalls of the next cycle. Still learning every day. youtu.be/WVO_lJijUP8

We are actively looking for RA for our startup. Please DM for further details.

@Value2WealthIND TAL hospitals have launched a live webinar product where in engagement with real patients would become possible. A good step forward. Link to the youtube recording of one of first webinars below. youtu.be/N6SYs79Ubaw?si…

Must watch interview of Dr Raju Pusapati (Ph.D.) Vice President of Life Sciences at Solix (TechNVision) Solix technologies (TechNVision) is only IT product company from small cap world which has products for AI Drug Discovery . Solix Technologies and Symbiosis International University have recently established a strategic partnership to launch a Center of Excellence (CoE) for AI-Driven Drug Discovery and Repurposing. youtu.be/9bth0vsnXE4

Completely agree , sooner or later the market will realize it .

Oh , that is really good news .I was not aware of it . Thanks for sharing.

TechNVision leadership team depth is one of the best in AI industry for this size, a rare confluence of vision , execution, and AI expertise with deep AI and platform DNA .It is enhanced more by this team .